Tobi Articles
Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told
9 December 2009
Pfizer and B&L to co-promote ophthalmics
9 March 2009
PDCO gives go ahead for 13 new PIPs
23 February 2009
Axentis boasts strength in presentation
9 February 2009
Novartis to acquire Nektar unit for $115M
27 October 2008
Expert updates on current CF pipeline
13 October 2008
Gilead submits inhalable aztreonam NDA
26 November 2007
Gilead's CF drug positive in Ph III trial
4 June 2007
Gilead reports full data from CF drug trial
30 April 2007
Gilead's aztreonam meets Ph III endpoint
22 December 2006
Chiron posts 12% sales jump on flu vacc return
13 February 2006
Chiron settles with RDN over tobramycin
14 March 2005
Stock Commentary - New York
14 March 2005
Bausch & Lomb's Zylet OKed in the USA
20 December 2004
3rd-qtr profit for Chiron despite Fluvirin woes
1 November 2004
Approvable letter for B&L's ophthalmic
16 August 2004
FDA accepts B&L and Pharmos' combo eye filing
10 November 2003
Chiron settles tobramycin patent dispute with Roxane
20 October 2003
Profile gets first drug license for Promixin
3 March 2003
Chiron Corp 2001 revenues top $1 bill
11 February 2002
Promising Ph I tobramycin results
4 October 2001
Chiron completes PathoGenesis purchase
25 September 2000
PathoGenesis' TOBI approved in EU
23 August 2000
Chiron Corp to acquire PathoGenesis for $700 million in cash
15 August 2000
PathoGenesis expects $20.2 mill 2nd-qtr sales
7 July 2000
Dutch subsidiary for PathoGenesis
6 April 2000
PathoGenesis establishes French subsidiary
2 February 2000
PathoGenesis gains UK approval for TOBI
21 December 1999
TOBI shows long-term efficacy in CF
13 October 1999
PathoGenesis invests in German partner
3 June 1999
1st-qtr sales to be lower at PathoGenesis
29 March 1999
New Approaches To CF Show Early Promise
20 October 1998
TOBI Filed In Europe
20 August 1998
Pathogenesis' TOBI
29 July 1998
Successful TOBI Launch Boosts PathoGenesis
28 May 1998
Pathogenesis Files For TOBI Approval In Canada
26 March 1998
US Biotech Ends Year "Slightly Ahead" Of 1996
21 January 1998
TOBI Granted Orphan Drug Status
13 January 1998
First Launch For PathoGenesis' TOBI
5 January 1998
PathoGenesis Corp's Tobi Recommended For Approval
27 November 1997
PathoGenesis Begins Phase II TOBI Trial
16 October 1997
PathoGenesis Explores New TOBI Indication
18 September 1997
PathoGenesis Files For TOBI
17 July 1997
Magainin Moves Nearer To Marketing Peptide Antibiotic
22 April 1997
PathoGenesis Prices 2.1 Mill Shares
7 April 1997
PathoGenesis Nears First NDA Filing
10 February 1997
Analyst's Rcommendation For Pharmos
16 December 1996
PathoGenesis Drug Shows Activity vs TB
14 October 1996
Akorn: Generic Tobramycin
12 February 1996
CYSTIC FIBROSIS; WHAT COMES AFTER PULMOZYME?
7 March 1994
EXTENSION TO JAPANESE FORMULARY
11 October 1993
US RESEARCH INTO CYSTIC FIBROSIS
12 July 1993
NONABSORBABLE ANTIBIOTICS
9 March 1992
Showing 1-63 of 63 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
